PURPOSE: Micropapillary (MP) bladder cancer is a rare variant of urothelial carcinoma (UC) which has been associated with an aggressive natural history. We sought to report the outcomes of patients with MP bladder cancer treated with radical cystectomy (RC) and compare survival to patients with pure UC of the bladder. METHODS: We identified 73 patients with MP bladder cancer and 748 patients with pure UC who underwent RC at our institution with median postoperative follow-up of 9.6 years. MP patients were stage-matched 1:2 to patients with pure UC. Survival was estimated using the Kaplan-Meier method and compared with the log-rank test. RESULTS: MP cancers were associated with a high rate of adverse pathologic features, as 48/73 patients (66 %) had pT3/4 tumors and 37 (50 %) had pN+ disease. Ten-year cancer-specific survival in MP patients was 31 %, compared with 53 % in the overall cohort with pure UC (p = 0.001). When patients with MP bladder cancer were then stage-matched to those with pure UC, no significant differences between the groups were noted with regard to 10-year local recurrence-free survival (62 vs. 69 %; p = 0.87), distant metastasis-free survival (44 vs. 56 %; p = 0.54), or cancer-specific survival (31 vs. 40 %; p = 0.41). CONCLUSION: MP cancers are associated with a higher rate of locally advanced disease. However, when matched to patients with pure UC, patients with MP tumors did not have increased local/distant recurrence or adverse cancer-specific survival following RC.
PURPOSE:Micropapillary (MP) bladder cancer is a rare variant of urothelial carcinoma (UC) which has been associated with an aggressive natural history. We sought to report the outcomes of patients with MP bladder cancer treated with radical cystectomy (RC) and compare survival to patients with pure UC of the bladder. METHODS: We identified 73 patients with MP bladder cancer and 748 patients with pure UC who underwent RC at our institution with median postoperative follow-up of 9.6 years. MP patients were stage-matched 1:2 to patients with pure UC. Survival was estimated using the Kaplan-Meier method and compared with the log-rank test. RESULTS:MP cancers were associated with a high rate of adverse pathologic features, as 48/73 patients (66 %) had pT3/4 tumors and 37 (50 %) had pN+ disease. Ten-year cancer-specific survival in MP patients was 31 %, compared with 53 % in the overall cohort with pure UC (p = 0.001). When patients with MP bladder cancer were then stage-matched to those with pure UC, no significant differences between the groups were noted with regard to 10-year local recurrence-free survival (62 vs. 69 %; p = 0.87), distant metastasis-free survival (44 vs. 56 %; p = 0.54), or cancer-specific survival (31 vs. 40 %; p = 0.41). CONCLUSION:MP cancers are associated with a higher rate of locally advanced disease. However, when matched to patients with pure UC, patients with MP tumors did not have increased local/distant recurrence or adverse cancer-specific survival following RC.
Authors: Christina B Ching; Mahul B Amin; Raymond R Tubbs; Paul Elson; Eric Platt; Robert Dreicer; Amr Fergany; Donna E Hansel Journal: Mod Pathol Date: 2011-04-22 Impact factor: 7.842
Authors: Ankur R Sangoi; Andrew H Beck; Mahul B Amin; Liang Cheng; Jonathan I Epstein; Donna E Hansel; Kenneth A Iczkowski; Antonio Lopez-Beltran; Esther Oliva; Gladell P Paner; Victor E Reuter; Jae Y Ro; Rajal B Shah; Steven S Shen; Pheroze Tamboli; Jesse K McKenney Journal: Am J Surg Pathol Date: 2010-09 Impact factor: 6.394
Authors: Tamara L Lotan; Huihui Ye; Jonathan Melamed; Xue-Ru Wu; Ie-Ming Shih; Jonathan I Epstein Journal: Am J Surg Pathol Date: 2009-07 Impact factor: 6.394
Authors: Ashish M Kamat; Jason R Gee; Colin P N Dinney; H Barton Grossman; David A Swanson; Randall E Millikan; Michelle A Detry; Tracy L Robinson; Louis L Pisters Journal: J Urol Date: 2006-03 Impact factor: 7.450
Authors: Ashish M Kamat; Colin P N Dinney; Jason R Gee; H Barton Grossman; Arlene O Siefker-Radtke; Pheroze Tamboli; Michelle A Detry; Tracy L Robinson; Louis L Pisters Journal: Cancer Date: 2007-07-01 Impact factor: 6.860
Authors: Daniel L Willis; Mario I Fernandez; Rian J Dickstein; Sahil Parikh; Jay B Shah; Louis L Pisters; Charles C Guo; Samuel Henderson; Bogdan A Czerniak; H Barton Grossman; Colin P Dinney; Ashish M Kamat Journal: J Urol Date: 2014-09-22 Impact factor: 7.450
Authors: Alexandra Masson-Lecomte; Pierre Colin; Gregory Bozzini; Laurent Nison; Alexandre de La Taille; Eva Comperat; Marc Zerbib; François Rozet; Xavier Cathelineau; Antoine Valeri; Alain Ruffion; Laurent Guy; Stéphane Droupy; Olivier Cussenot; Morgan Rouprêt Journal: World J Urol Date: 2013-08-02 Impact factor: 4.226
Authors: Daniel L Willis; Thomas W Flaig; Donna E Hansel; Matthew I Milowsky; Robert L Grubb; Hikmat A Al-Ahmadie; Elizabeth R Plimack; Theresa M Koppie; David J McConkey; Colin P Dinney; Vanessa A Hoffman; Michael J Droller; Edward Messing; Ashish M Kamat Journal: Urol Oncol Date: 2014-06-13 Impact factor: 3.498
Authors: Alexandra Masson-Lecomte; Evanguelos Xylinas; Morgane Bouquot; Mathilde Sibony; Yves Allory; Eva Comperat; Marc Zerbib; Alexandre de la Taille; Morgan Rouprêt Journal: World J Urol Date: 2014-09-02 Impact factor: 4.226
Authors: Sumit Isharwal; Hongying Huang; Gouri Nanjangud; François Audenet; Ying-Bei Chen; Anuradha Gopalan; Samson W Fine; Satish K Tickoo; Byron H Lee; Gopa Iyer; Kalyani Chadalavada; Jonathan E Rosenberg; Dean F Bajorin; Harry W Herr; S Machele Donat; Guido Dalbagni; Bernard H Bochner; David B Solit; Victor E Reuter; Hikmat A Al-Ahmadie Journal: Hum Pathol Date: 2018-03-27 Impact factor: 3.466
Authors: Ofer N Gofrit; Vladimir Yutkin; Amos Shapiro; Galina Pizov; Kevin C Zorn; Guy Hidas; Ilan Gielchinsky; Mordechai Duvdevani; Ezekiel H Landau; Dov Pode Journal: Front Oncol Date: 2016-03-15 Impact factor: 6.244